Evidence map›Paper›PMID 26894870›Full record

ArticleBiomaterials2016

Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.

Nicholas M Molino, Medea Neek, Jo Anne Tucker, Edward L Nelson, Szu-Wen Wang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Nanomaterials and Their Impact on the Immune System.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nicholas M MolinoDepartment of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA.
Medea NeekDepartment of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA.
Jo Anne TuckerDepartment of Medicine, University of California, Irvine, CA 92697, USA.
Edward L NelsonDepartment of Medicine, University of California, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA; Institute for Immunology, University of California, Irvine, CA 92697, USA.
Szu-Wen WangDepartment of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA; Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA. Electronic address: wangsw@uci.edu.
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
Nanoparticle-Modulated Response Against Tumor-Associated AntigensR21EB017995 · NIBIB · UNIVERSITY OF CALIFORNIA-IRVINE · PI WANG, SZU-WEN · 2014 to 2015
$380k
NCI NIH HHS P30 CA062203NCI NIH HHS P30CA062203NIBIB NIH HHS R21 EB017995NIBIB NIH HHS R21EB017995
6 · The paper itself

Abstract

The immune system is a powerful resource for the eradication of cancer, but to overcome the low immunogenicity of tumor cells, a sufficiently strong CD8(+) T cell-mediated adaptive immune response is required. Nanoparticulate biomaterials represent a potentially effective delivery system for cancer vaccines, as they can be designed to mimic viruses, which are potent inducers of cellular immunity. We have been exploring the non-viral pyruvate dehydrogenase E2 protein nanoparticle as a biomimetic platform for cancer vaccine delivery. Simultaneous conjugation of a melanoma-associated gp100 epitope and CpG to the E2 nanoparticle (CpG-gp-E2) yielded an antigen-specific increase in the CD8(+) T cell proliferation index and IFN-γ secretion by 1.5-fold and 5-fold, respectively, compared to an unbound peptide and CpG formulation. Remarkably, a single nanoparticle immunization resulted in a 120-fold increase in the frequency of melanoma epitope-specific CD8(+) T cells in draining lymph nodes and a 30-fold increase in the spleen, relative to free peptide with free CpG. Furthermore, in the very aggressive B16 melanoma murine tumor model, prophylactic immunization with CpG-gp-E2 delayed the onset of tumor growth by approximately 5.5 days and increased animal survival time by approximately 40%, compared to PBS-treated animals. These results show that by combining optimal particle size and simultaneous co-delivery of molecular vaccine components, antigen-specific anti-tumor immune responses can be significantly increased.

Indexed as

CpG IslandsAnimalsBiomimeticsCancer VaccinesCD8-Positive T-LymphocytesCells, CulturedDrug Delivery SystemsEpitopesFemalegp100 Melanoma AntigenHumansImmunizationInterferon-gammaMelanoma, ExperimentalMiceMice, Inbred C57BLCancer VaccinesEpitopesgp100 Melanoma AntigenInterferon-gammaPyruvate Dehydrogenase ComplexBiomimeticCD8Protein nanoparticleT cellsTumor-associated antigenVaccine

Identifiers

PMID26894870
PMCPMC4775383
OpenAlexW2265709812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.